Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Lisata Therapeutics ( (LSTA) ).
On August 7, 2025, Lisata Therapeutics announced its financial results for the second quarter of 2025 and provided a business update. The company reported a strong cash position with funds projected to support operations into the fourth quarter of 2026, including ongoing clinical studies. Lisata highlighted positive preliminary results from its ASCEND and iLSTA trials, showcasing the potential of certepetide in enhancing the effectiveness of standard cancer treatments. The company is advancing multiple clinical trials globally, with significant progress in its development portfolio, including the ASCEND, BOLSTER, CENDIFOX, and iLSTA trials, which are expected to provide further data and insights into the efficacy of certepetide in treating various solid tumors.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for the treatment of advanced solid tumors and other serious diseases. The company is primarily engaged in exploiting the broad applicability of certepetide, a proprietary investigational drug, across various difficult-to-treat indications.
Average Trading Volume: 31,894
Technical Sentiment Signal: Hold
Current Market Cap: $25.11M
See more data about LSTA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money